Clinical trial
A Phase III Randomized, Open-Label Clinical Trial of BBI-608 Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer
NCT02826161 is registered in ClinicalTrials.gov with Sumitomo Pharma America, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Randomized, Open-Label Clinical Trial of BBI-608 Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- November 30, 2016
- Completion date
- April 24, 2017
- Enrollment
- 4 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.